Bench to Bedside: Therapeutics
Preclinical Candidate to Commercial Therapy
The learning framework
The therapy that worked and could not be made
A company reports positive clinical results. The mechanism is validated, the endpoint is met, and the data is genuinely good. Then the manufacturing question arrives. The material used in the trial was made at a scale and a cost that has no relationship to commercial supply. Moving to commercial scale requires a process change, a process change requires comparability data showing the new material behaves like the old, and generating that data takes time the company does not have because the clinical result has already started the clock on competitors and on investor expectations. The company raises again, from a position of apparent strength but real urgency, on terms set by the gap between what it has proven and what it can supply. The science was never the problem. The CDMO selected three years earlier, chosen because it was available and affordable at preclinical scale, could not follow the product to commercial volume, and that was knowable at the time.
Why manufacturing is planned last and costs the most
Therapeutic development is organized around the clinic. Milestones are phases, value inflections are readouts, and the entire vocabulary of the industry is clinical. Manufacturing appears as a supporting function that supplies material for the trials. That framing is accurate operationally and wrong financially. CMC work runs on its own timeline, gates the clinical program more often than founders expect, and is the item most likely to delay a filing. For biologics, and far more so for cell and gene therapies, the process is a substantial part of the product itself, which means a change to the process is a change to the product and has to be proven not to be. The consequence is a set of decisions made early and quietly with effects that surface years later. A CDMO chosen for preclinical convenience. A process developed for a scale that will not be the commercial scale. Analytical methods that were adequate for a phase I release and will not support a commercial specification. None of these looks like a strategic decision at the time it is made.
A clinical plan and a supply plan built together
Healthcare innovators who complete this evolution plan the clinical program and the manufacturing program as one sequence rather than as a primary activity and a supporting one. They can identify which CMC milestones gate which clinical milestones, and which of those gate a financing. They evaluate a CDMO as a multi-year structural commitment with consequences for cost of goods, for tech transfer risk, and for what an acquirer inherits, rather than as a vendor selection made on price and availability. And they understand where in their own program the manufacturing risk concentrates, because for a small molecule, a biologic, and a cell therapy it concentrates in different places.
By the end of this evolution, you will be able to:
Select and structure a CDMO relationship
Evaluate a contract development and manufacturing organization as a multi-year structural commitment. Understand scale capability, technology fit, capacity allocation, tech transfer terms, intellectual property in the process, exclusivity, and what happens if you outgrow them or need to leave. This decision has more downstream consequence than any other on this page.
Treat IND strategy as a capital decision
Understand what the filing requires across preclinical, toxicology, and CMC, what each costs, and how the timing of the filing interacts with your financing plan. Recognize which elements can run in parallel and which cannot.
Sequence the clinical program against the financing plan
Map phases and readouts to the raises they enable. Understand which results change what the company is worth, how long each phase actually takes including startup and enrollment, and why the gap between a readout and the next tranche of capital is where companies fail.
Manage enrollment risk as a financial variable
Understand why clinical programs run long, what site selection and eligibility criteria do to enrollment rate, and why a trial that cannot be paused mid-enrollment forces a financing at the moment of least leverage.
Read CMC milestones as funding triggers
Identify which chemistry, manufacturing, and controls milestones gate clinical progress and which gate a financing. Understand why CMC is the most common cause of a delayed filing and the least commonly modeled item in a capital plan.
Plan the scale-up before you need it
Understand the gap between material made for a trial and material made for a market: process change, comparability, analytical method validation, and the time each takes. Learn why this gap strands companies after a successful readout.
Understand where the risk sits for your modality
Small molecules, biologics, and cell and gene therapies concentrate manufacturing risk in different places. Learn to identify where yours sits, and why a cell therapy in which the process is substantially the product cannot be managed like a small molecule.
Build a therapeutic asset an acquirer can absorb
Understand what a buyer inherits: a process, a supply relationship, a regulatory file, and comparability history. Learn why an asset with clean, transferable manufacturing is worth more than one with equivalent data and a supply problem.
Why this matters
Recommended for
Healthcare innovators navigating:
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
Clinical success without commercial supply is not success.